- Home
- RMMZ vs INO Comparison
RMMZ vs INO Comparison
Compare RMMZ & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMMZ | INO |
|---|---|---|
| Founded | 2022 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.9M | 136.6M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | RMMZ | INO |
|---|---|---|
| Price | $14.70 | $2.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 25.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | N/A | ★ $182,337.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21,219.94 |
| P/E Ratio | $19.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.92 | $1.30 |
| 52 Week High | $16.99 | $4.08 |
Technical Indicators
Market Signals| Indicator | RMMZ | INO |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 59.44 |
| Support Level | $14.68 | $1.86 |
| Resistance Level | $14.88 | $2.27 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 48.99 | 82.94 |
Price Performance
Historical ComparisonAbout RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.